LYONS, France - Poxel SAS is Set up in Lyons - France
Poxel is a research integrated pharmaceutical Company (RIPCO), spun out from Merck Serono a division of Merck KGaA, Germany, following the decision of Merck Serono to no longer invest in diabetes research and development. It aims to advance promising assets for cardio-metabolic diseases (with a primary focus on Type 2 diabetes) from Research to Phase 2 Clinical Proof-of-Concept, before out-licensing these projects to major pharmaceutical companies.
Its pipeline consists only of innovative projects with new mechanisms of action, with a combined activity on glucose metabolism and other cardiovascular risk factors (lipid disorders and obesity) and with an improved safety profile compared to currently available therapies.
Poxel has secured several programs from the Merck Serono pipeline. These include a first-in-class project, Imeglimin -which has already achieved its clinical proof-of-concept for the Type 2 diabetes monotherapy indication- and other projects from the Research until close to clinical development stages.
Poxel’s management is composed of a tight and seasoned team of professionals who previously led the Merck Serono diabetes franchise from Research to Clinical & Commercialization. They have a proven track record in the pharmaceutical industry and extensive skills both in project management and technical expertise. The whole management team has an integrated strategic and operational view of the product value chain, from Research to Marketing, covering the complete product life cycle.
Poxel’s team will perform and coordinate all work required in the following areas: research, preclinical, clinical and business development, with a strong focus on cardio-metabolic diseases.
A focused and streamlined development of the company assets will ensure a successful out-licensing of those assets.
All this provides Poxel with a significant competitive advantage.
Poxel’s team will be advised by a highly regarded scientific Advisory Board in Endocrinology and Nutrition from the US and Europe.
Poxel will start the development of its core assets, while seeking funding in order to create additional value from its unique pipeline. Neither Merck KGaA nor Merck Serono is shareholders of Poxel.
About Type 2 Diabetes:
Type 2 Diabetes is defined by a failure of sensitive tissues to respond to insulin, a hormone involved in glucose and fatty acid metabolism, Type 2 diabetes hence being known as non-insulin-dependent diabetes. 90% of diabetic patients in the world suffer from type 2 diabetes.
In 2007, more than 220 million people suffered from Type 2 diabetes worldwide, including over 65 million patients in the US and Europe. It is predicted that more than 300 million patients will have this disease by 2025 (IDF).
The market is about EUR bn9.6 turnover in 2007, expected to reach EUR bn15 by 2016.
Existing therapies on the market are dominated by few dominant product classes, but significant unmet needs remain.
About Poxel:
Poxel is a new RIPCO that aims to advance promising assets for cardio-metabolic diseases from Research to Phase 2 Clinical Proof of Concept, before out licensing projects to pharmaceutical companies. Poxel will further develop its portfolio by considering all opportunities corresponding to its core domain of competencies.
Visit Poxel’s website: www.poxelpharma.com
Source: Poxel SAS
For further information, please contact: Mr Thomas Kuhn, Poxel CEO, +33-6-69-21-47-89; Mrs Pascale Malgouyres, Poxel Business Development Director, +33-6-98-01-71-92.
Related Press Releases
Merck Serono Growth Hormone Injection Device easypod(R) Approved in JapanSeptember 15th, 2009 GENEVA - Merck Serono, a division of Merck KGaA Darmstadt, Germany, today announced that the Japanese health authorities, the Pharmaceutical and Medical Devices Agency (PMDA), have granted a marketing authorization for easypod(R) in Japan. Easypod(R) was developed for exclusive use with cartridges of Saizen(R) (somatropin), Merck Serono's human recombinant growth hormone for the treatment of growth hormone deficiency.
/C O R R E C T I O N -- Merck Serono S A/September 15th, 2009 GENEVA - In the news release, "Merck Serono Growth Hormone Injection Device easypod(R) Approved in Japan" issued on 16 Sep 2009 07:00 GMT, by Merck Serono S A SWX:SEO over PR Newswire, we are advised by a representative of the company that the last sentence of the fourth paragraph has been changed from "In Japan, easypod(R) will be launched in September 2009" to "In Japan, easypod(R) will be launched in the course of 2009" as originally issued inadvertently. Complete, corrected release follows:
Merck Serono, a division of Merck KGaA Darmstadt, Germany, today announced that the Japanese health authorities, the Pharmaceutical and Medical Devices Agency (PMDA), have granted a marketing authorization for easypod(R) in Japan.
Chora Council of the Metabolic Studio Announces the Winner of the Chora PrizeAugust 26th, 2009 PANTELLERIA, Italy -
- First Recipient, Artist Felicity Powell, to Receive Award On October 2, 2009 at Metabolic Studio
The Chora Council, which supports the intangibles that foster creativity, is proud to announce the winner of the first Chora Prize. Artist Felicity Powell will receive US$50,000 to acknowledge her fully realized project of merit and originality, an exhibition entitled Medals of Dishonour, currently at the British Museum in London through September 27, 2009.
Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic DisordersAugust 23rd, 2009 HOERSHOLM, Denmark -
- Santaris Pharma A/S and Shire plc to Engage in a Multi-Year Research Program Utilizing Santaris Pharma's Proprietary Locked Nucleic Acid (LNA) Drug Platform to Identify and Select Drug Candidates Against Certain Targets for the Treatment of Rare Genetic Disorders
- Santaris Pharma A/S to Receive Significant Upfront Payments, Milestone Payments and Royalties for Providing Access to its LNA Technology, Exclusivity for Three Pre-Defined Targets and Funding for Discovery
- Partnership for the Treatment of Rare Genetic Disorders Further Demonstrates Versatility of the LNA Drug Platform to Develop RNA-Based Medicines for a Range of Disease Areas Including Metabolic Disorders, Cancer, Infectious and Inflammatory Diseases
Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, today announced a multi-year worldwide strategic alliance with Shire plc to discover and develop new RNA-based medicines to treat rare genetic disorders. (Logo: www.newscom.com/cgi-bin/prnh/20090420/344344 )
The alliance will use Santaris Pharma A/S' proprietary Locked Nucleic Acid (LNA) Drug Platform to identify and select drug candidates against certain targets.
New Consortium to Develop Drugs for Neglected Tropical DiseasesAugust 16th, 2009 LEIDEN, The Netherlands - A new consortium has been formed to boost drug development for the treatment of two deadly diseases, African sleeping sickness and Leishmaniasis, which affect millions of people worldwide. A total budget of nearly 3.6 million euros has been allocated over the next 4 years, to develop effective drugs for these diseases.
Merck Serono Committed to Investing in Innovation in the Fertility AreaMay 17th, 2009 GENEVA, Switzerland - Merck Serono, a division of Merck KGaA, Darmstadt, Germany, confirms its commitment to investing in the therapeutic area of fertility, after Merck KGaA informed earlier today the Oslo Stock Exchange of its withdrawal of the voluntary cash tender offer for MediCult A/S, a leader in Assisted Reproductive Technologies (ART), as the required share threshold was not reached in the set timeframe. "Merck Serono has a proud heritage of leadership in the field of fertility and will actively pursue opportunities that will contribute to bring further innovation to physicians and patients, and increase the success rate of fertility treatments," said Dr.
Accera, Inc. Launches Neuera Pharmaceuticals, Inc.April 14th, 2009 BROOMFIELD, Colorado - New Business Spin-off to Focus on Drug Development for Neurological Conditions
Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system (CNS) diseases, announced today the formation of Neuera Pharmaceuticals, Inc., a drug development company. The new company will focus on the discovery and development of proprietary small molecule drugs for acute and chronic neurological conditions where the mechanism of defective energy metabolism or hypometabolism is involved.
BioDuro and Roche Expand Strategic Collaboration to Provide Drug Discovery ServicesApril 5th, 2009 BEIJING - BioDuro announced today that they have entered into a strategic partnership with Roche to support discovery phase research efforts at Roche's global research sites. BioDuro will provide research services in the areas of discovery chemistry and biology, which can help to shorten (internal) drug discovery timelines.
Dr. Thomas Werner Elected to Accera, Inc.'s Board of DirectorsMarch 23rd, 2009 BROOMFIELD, Colorado - Accera, Inc., a biotechnology company delivering breakthrough therapies
in central nervous system (CNS) diseases, announced today that Thomas Werner,
Ph.D. has been elected to its board of directors.
The French Institute I-Stem Realizes First Innovative Screens Using Stem Cells to Identify Drugs for Myotonic Dystrophy, DM1 DiseaseMarch 18th, 2009 EVRY, France - Four research teams of I-STEM[*] have joined forces in a collaborative
project that has just achieved a first pilot therapy-oriented screen of
compounds and RNA interference aiming at reversing the altered phenotypes
observed in human embryonic stem cells carrying the mutant gene for myotonic
dystrophy type1. This assay inaugurates a series of R&D planned in 2009.
Related News
New test to track mysterious metabolic diseases developedFebruary 11th, 2009 WASHINGTON - Scientists have devised a much-needed way to monitor and find treatment for a mysterious and devastating group of metabolic diseases that arise from mutations in cells' fuel-burning mechanism. Mitochondrial disorders can cause organ failure, seizures, stroke-like episodes and premature death.
Now, a metabolic 'fingerprint' for personalized medical careJuly 23rd, 2009 WASHINGTON - Fingerprints as a marker of your unique identity could soon be obsolete, for scientists have now found that people have another defining trait that may distinguish them from the rest of the human population-a metabolic fingerprint. In the study, the researchers have reported evidence of the existence of unique patterns in metabolism in humans.
'India can boost exports only through better product designs'August 20th, 2009 NEW DELHI - India's exports can only be sustained if large and small companies designed globally competitive products, said a global innovative solutions provider here Thursday. "The product may be best in technology but it must also look good.
High-fat diet can not be given to kids without medical managementApril 8th, 2009 WASHINGTON - A high-fat therapy comprising whipped cream, butter and vegetable oil to reduce seizures in kids, requires long-term medical management and parental commitment. The study, by Mary L.
Textron unit names picks for chief innovative officer and chief technology officerAugust 27th, 2009 Textron Systems names 2 executive postsWILMINGTON, Mass. — A unit of industrial conglomerate Textron Inc.
AIG sells Canadian operations for $375 millionJanuary 13th, 2009 TORONTO - Bank of Montreal (BMO) Tuesday announced it is buying Canadian business of the troubled global insurance giant American International Group (AIG). The bank said it is acquiring the AIG Life Insurance Company of Canada (AIG Life of Canada) for $375 million in cash.
3-D kidney atlas to help researchers, physicians treat renal diseasesMay 16th, 2009 WASHINGTON - In a bid to diagnose and treat renal diseases early and more successfully, researchers from nine European countries have spent four-and-a half years to create a three-dimensional virtual "Kidney Atlas", which incorporates the latest research findings on the development and diseases of the kidney. The Kidney Atlas was part of the European Renal Genome Project (EuReGene), coordinated by the Max Delbruck Center for Molecular Medicine (MDC) Berlin-Buch, Germany, which the European Union (EU) funded with more than 10 million euros.
Migrating birds chill at stopovers to save energySeptember 11th, 2009 WASHINGTON - In a new research, scientists have suggested that migrating birds drop their body temperature at night during stopovers to save energy and build up their reserves faster. Scientists Michal Wojciechowski and Berry Pinshow carried out the research.
SCO should find solutions for regional issues: ZardariJune 16th, 2009 YEKATERINBURG - Pakistan President Asif Ali Zardari said Tuesday that the Shanghai Cooperation Organization (SCO) should help find solutions to regional problems and proposed a special mechanism for his country's involvement in three key areas - security, energy and trade. There was need to find concrete solutions instead of stop-gap arrangements, Zardari said while addressing the ninth SCO summit in this Russian industrial city, adding SCO must help finding solutions to regional problems, Online news agency reported.
With lifestyle diseases on the rise, healthcare should be future focus: AnsariSeptember 10th, 2009 RANCHI - Vice President M Hamid Ansari on Thursday said with the number of lifestyle diseases increasing, healthcare facilities should be strengthened to meet future demands of the country. "The facilities we have is sufficient for now, but not sufficient for future," Ansari said while dedicating the new HCG Curie-Abdur Razzaque Ansari Cancer Institute (C-ARACI) to the nation.
